Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022. That same day, Mirum will host a conference call to discuss the company’s progress and priorities for 2022.

Conference call details: Thursday, August 4, 2022 4:30 p.m. ET / 1:30 p.m. PT

Dial-in: U.S./Toll-Free: 1 (888) 510-2553 International: 1 (646) 960-0473 Passcode: 9354200

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

Media Contact: Erin Murphy media@mirumpharma.com

Investor Contacts: Ian Clements, Ph.D. ir@mirumpharma.com

Sam Martin Argot Partners ir@mirumpharma.com

Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Mirum Pharmaceuticals Charts.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Mirum Pharmaceuticals Charts.